Identification

Name
Trimipramine
Accession Number
DB00726  (APRD00498)
Type
Small Molecule
Groups
Approved
Description

Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]

Structure
Thumb
Synonyms
  • 10,11-dihydro-N,N,beta-Trimethyl-5H-dibenz[b,F]azepine-5-propanamine
  • 5-(gamma-dimethylamino-beta-Methylpropyl)-10,11-dihydro-5H-dibenzo[b,F]azepine
  • 5-[3-(dimethylamino)-2-Methylpropyl]-10,11-dihydro-5H-dibenz[b,F]azepine
  • beta-Methylimipramine
  • RP-7162
  • Sapilent
  • Trimeprimina
  • Trimeprimine
  • Trimeproprimine
  • Trimipramina
  • Trimipramine
  • Trimipraminum
External IDs
IF 6120 / IL 6001 / RP 7162
Product Ingredients
IngredientUNIICASInChI Key
Trimipramine maleate269K6498LD521-78-8YDGHCKHAXOUQOS-BTJKTKAUSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RhotrimineTablet100 mgOralSanofi Aventis1988-12-312007-03-29Canada
RhotrimineTablet12.5 mgOralSanofi Aventis1988-12-312006-07-28Canada
RhotrimineTablet50 mgOralSanofi Aventis1988-12-312006-07-28Canada
RhotrimineCapsule75 mgOralSanofi Aventis1988-12-312007-03-29Canada
RhotrimineTablet25 mgOralSanofi Aventis1988-12-312006-07-28Canada
SurmontilCapsule25 mg/1OralTeva Women's Health1990-09-30Not applicableUs51285 0538 02 nlmimage10 9f304fb2
SurmontilCapsule100 mg/1OralTeva Women's Health1990-09-30Not applicableUs51285 0554 02 nlmimage10 d6366b13
SurmontilTablet25 mgOralSanofi Aventis1964-12-312006-07-28Canada
SurmontilCapsule50 mg/1OralTeva Women's Health1990-09-30Not applicableUs51285 0539 02 nlmimage10 d13068d3
SurmontilTablet50 mgOralSanofi Aventis1971-12-312006-07-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trimipramineTablet25 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineTablet100 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineTablet12.5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineTablet50 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-trimipramineCapsule75 mgOralApotex CorporationNot applicableNot applicableCanada
Novo-tripramine Tab 100mg BPTablet100 mgOralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 25mg BPTablet25 mgOralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 50mg BPTablet50 mgOralNovopharm Limited1991-12-312015-10-26Canada
Nu-trimipramine Tab 100mgTablet100 mgOralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 12.5mgTablet12.5 mgOralNu Pharm Inc1993-12-312012-09-04Canada
International/Other Brands
Herphonal (Temmler) / Sapilent (ExtractumPharma) / Stangyl (Sanofi-Aventis) / Trimidura (Mylan dura) / Trimineurin (Hexal) / Tripress (Mylan) / Tydamine (Aspen Pharmacare)
Categories
UNII
6S082C9NDT
CAS number
739-71-9
Weight
Average: 294.4338
Monoisotopic: 294.209598842
Chemical Formula
C20H26N2
InChI Key
ZSCDBOWYZJWBIY-UHFFFAOYSA-N
InChI
InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}-2-methylpropyl)dimethylamine
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12

Pharmacology

Indication

For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance

Associated Conditions
Pharmacodynamics

Trimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of action

Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
USodium-dependent dopamine transporter
inhibitor
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UD(2) dopamine receptor
other/unknown
Human
UAlpha-2B adrenergic receptor
other/unknown
Human
UHistamine H1 receptor
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
binder
Human
U5-hydroxytryptamine receptor 1D
binder
Human
UAlpha-2A adrenergic receptor
desensitize the target
Human
UD(1) dopamine receptor
binder
Human
UBeta adrenergic receptor
binder
Human
UMuscarinic acetylcholine receptor
binder
Human
U5-hydroxytryptamine receptor 1C
binder
Rat
Absorption

Rapid absorption

Volume of distribution
Not Available
Protein binding

93%-96% (to plasma proteins)

Metabolism

Hepatic

Route of elimination
Not Available
Half life

11-18 hrs

Clearance
Not Available
Toxicity

Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2C19CYP2C19*2Not Available681G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe serum concentration of Trimipramine can be increased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe serum concentration of Trimipramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineTrimipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineTrimipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Trimipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineTrimipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Trimipramine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineTrimipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineTrimipramine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Trimipramine.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Abediterol.Investigational
AbirateroneThe serum concentration of Trimipramine can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
AcenocoumarolTrimipramine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineTrimipramine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Trimipramine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Trimipramine is combined with Adipiplon.Investigational
AdrafinilTrimipramine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Trimipramine.Approved
AgmatineTrimipramine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trimipramine.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Trimipramine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Trimipramine can be increased when it is combined with Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Trimipramine.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Trimipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trimipramine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Trimipramine.Approved
AmibegronTrimipramine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe metabolism of Trimipramine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amisulpride.Approved, Investigational
AmitrazTrimipramine may decrease the antihypertensive activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Trimipramine.Approved
AmlodipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Trimipramine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the antihypertensive activities of Trimipramine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the serotonergic activities of Trimipramine.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Trimipramine can be increased when it is combined with Amprenavir.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Trimipramine is combined with Amrinone.Approved
AnagrelideTrimipramine may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineTrimipramine may decrease the vasoconstricting activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Trimipramine can be increased when it is combined with Antithrombin III human.Approved
ApalutamideThe serum concentration of Trimipramine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Trimipramine can be increased when it is combined with Apixaban.Approved
ApomorphineTrimipramine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineTrimipramine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Trimipramine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Trimipramine can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
AranidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Aranidipine.Approved, Investigational
ArbutamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Trimipramine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Trimipramine.Approved, Investigational
ArmodafinilThe metabolism of Trimipramine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Trimipramine.Investigational
Arsenic trioxideTrimipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTrimipramine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Articaine.Approved
AsenapineAsenapine may increase the antihypertensive activities of Trimipramine.Approved
AsunaprevirThe serum concentration of Trimipramine can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Trimipramine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
AtomoxetineThe metabolism of Trimipramine can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the hypotensive activities of Trimipramine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Azaperone.Investigational, Vet Approved
AzelastineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Trimipramine is combined with Azimilide.Investigational
AzithromycinTrimipramine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Trimipramine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Trimipramine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Trimipramine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Barnidipine.Approved
BatimastatThe serum concentration of Trimipramine can be increased when it is combined with Batimastat.Experimental
BedaquilineTrimipramine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Trimipramine.Experimental
BenazeprilThe serum concentration of Trimipramine can be increased when it is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Trimipramine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Trimipramine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Benperidol.Approved, Investigational
BenzamidineThe serum concentration of Trimipramine can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Benzocaine.Approved, Investigational
BenzphetamineTrimipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trimipramine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineTrimipramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Trimipramine is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Trimipramine.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
BethanidineTrimipramine may decrease the antihypertensive activities of Bethanidine.Approved
BevantololBevantolol may increase the antihypertensive activities of Trimipramine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bifeprunox.Investigational
BioallethrinThe risk or severity of hypotension can be increased when Trimipramine is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
BitolterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bitolterol.Withdrawn
BivalirudinThe serum concentration of Trimipramine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Trimipramine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
BortezomibThe metabolism of Trimipramine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Trimipramine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trimipramine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimipramine.Approved, Investigational
BrexpiprazoleTrimipramine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Trimipramine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trimipramine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bromisoval.Experimental
BromocriptineTrimipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Trimipramine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Trimipramine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Trimipramine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
BuprenorphineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Trimipramine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trimipramine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trimipramine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Trimipramine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Trimipramine is combined with Butamben.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Trimipramine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trimipramine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trimipramine.Approved
CamostatThe serum concentration of Trimipramine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Trimipramine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Trimipramine can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Trimipramine is combined with Canertinib.Investigational
CapecitabineThe metabolism of Trimipramine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Trimipramine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Trimipramine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Trimipramine is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Trimipramine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trimipramine.Approved
CaroverineThe risk or severity of hypotension can be increased when Trimipramine is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the serotonergic activities of Trimipramine.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Trimipramine.Approved, Investigational
CelecoxibThe metabolism of Trimipramine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
CeritinibThe serum concentration of Trimipramine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trimipramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Trimipramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trimipramine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Trimipramine can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorphenamine.Approved
ChlorphentermineTrimipramine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorproethazine.Experimental
ChlorpromazineTrimipramine may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trimipramine.Approved
CholecalciferolThe metabolism of Trimipramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Trimipramine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Trimipramine can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Trimipramine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Trimipramine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Trimipramine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinTrimipramine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineTrimipramine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideTrimipramine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Trimipramine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Trimipramine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clidinium.Approved
ClobazamThe metabolism of Trimipramine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clonazepam.Approved, Illicit
ClonidineTrimipramine may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Trimipramine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trimipramine.Approved, Illicit
ClorindioneTrimipramine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Trimipramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the antihypertensive activities of Trimipramine.Approved
CobicistatThe serum concentration of Trimipramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Trimipramine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trimipramine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Trimipramine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Trimipramine.Approved, Investigational
CrisaboroleThe metabolism of Trimipramine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Trimipramine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Trimipramine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyamemazine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Trimipramine is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Trimipramine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trimipramine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trimipramine.Approved
DabrafenibThe serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dantrolene.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Trimipramine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.Investigational
DarexabanThe serum concentration of Trimipramine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Trimipramine can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Darodipine.Experimental
DarunavirThe serum concentration of Trimipramine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Trimipramine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Trimipramine can be increased when it is combined with Delapril.Investigational
DelavirdineThe metabolism of Trimipramine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trimipramine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desvenlafaxine.Approved, Investigational
DetomidineTrimipramine may decrease the antihypertensive activities of Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine.Approved
DexmedetomidineTrimipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Trimipramine.Approved, Investigational
DextroamphetamineTrimipramine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trimipramine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trimipramine.Approved, Illicit, Investigational, Vet Approved
DicoumarolTrimipramine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Trimipramine is combined with Diethyl ether.Experimental
DiethylpropionTrimipramine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trimipramine.Approved, Illicit
DihydroergotamineTrimipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Trimipramine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dimenhydrinate.Approved
DiphenadioneTrimipramine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Trimipramine can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trimipramine.Approved, Illicit
DipivefrinTrimipramine may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Trimipramine.Approved
DisopyramideTrimipramine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dixyrazine.Experimental
DL-MethylephedrineTrimipramine may decrease the antihypertensive activities of DL-Methylephedrine.Approved
DobutamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dobutamine.Approved
DofetilideTrimipramine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronTrimipramine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneTrimipramine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopexamineTrimipramine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Trimipramine can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Trimipramine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Trimipramine.Approved
DoxepinDoxepin may increase the antihypertensive activities of Trimipramine.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Trimipramine.Approved, Investigational
DoxycyclineThe metabolism of Trimipramine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Trimipramine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved, Illicit
DronedaroneDronedarone may increase the antihypertensive activities of Trimipramine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Drotebanol.Experimental, Illicit
DroxidopaTrimipramine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Trimipramine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dyclonine.Approved
EcabetThe serum concentration of Trimipramine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Trimipramine.Approved
EfavirenzThe metabolism of Trimipramine can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Efonidipine.Approved, Investigational
ElafinThe serum concentration of Trimipramine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trimipramine.Approved, Investigational
EliglustatTrimipramine may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Eltanolone.Investigational
EnalaprilThe serum concentration of Trimipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Trimipramine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Trimipramine can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Trimipramine.Approved, Investigational
EnzalutamideThe serum concentration of Trimipramine can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Trimipramine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Trimipramine is combined with Eperisone.Approved, Investigational
EphedraTrimipramine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineTrimipramine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineTrimipramine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineTrimipramine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergonovine.Approved
ErgotamineTrimipramine may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinThe metabolism of Trimipramine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Trimipramine.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Trimipramine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
EsomeprazoleThe metabolism of Trimipramine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Trimipramine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trimipramine.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etafedrine.Approved
EthanolTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimipramine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethotoin.Approved
Ethyl biscoumacetateTrimipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etifoxine.Investigational, Withdrawn
EtilefrineTrimipramine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etizolam.Approved
EtomidateTrimipramine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Trimipramine can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trimipramine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ezogabine.Approved, Investigational
FaldaprevirThe serum concentration of Trimipramine can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Felbamate.Approved
FelodipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Trimipramine is combined with Fendiline.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fexofenadine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Trimipramine is combined with Fish oil.Approved, Nutraceutical
FlecainideTrimipramine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flibanserin.Approved, Investigational
FloxuridineThe metabolism of Trimipramine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Trimipramine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fludiazepam.Approved, Illicit
FluindioneTrimipramine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Trimipramine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimipramine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Trimipramine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trimipramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trimipramine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trimipramine.Approved
FluvastatinThe metabolism of Trimipramine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trimipramine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Trimipramine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Trimipramine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Trimipramine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Trimipramine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Trimipramine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Trimipramine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Trimipramine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trimipramine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Trimipramine is combined with Gabapentin Enacarbil.Approved, Investigational
GabexateThe serum concentration of Trimipramine can be increased when it is combined with Gabexate.Investigational
Gadobenic acidTrimipramine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Trimipramine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Trimipramine.Approved, Illicit, Investigational
GeldanamycinThe serum concentration of Trimipramine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Trimipramine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinTrimipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineTrimipramine may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Trimipramine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Trimipramine can be increased when it is combined with GM6001.Experimental
GoserelinTrimipramine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTrimipramine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzTrimipramine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineTrimipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Trimipramine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Trimipramine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Trimipramine can be increased when combined with Hexobarbital.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Hexoprenaline.Approved, Withdrawn
HigenamineTrimipramine may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trimipramine.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Trimipramine.Experimental
HydrocodoneTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimipramine.Approved, Illicit
HydroxyamphetamineTrimipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
IbutilideTrimipramine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe metabolism of Trimipramine can be decreased when combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Trimipramine can be increased when it is combined with Idraparinux.Investigational
IloperidoneTrimipramine may increase the antihypertensive activities of Iloperidone.Approved
ImatinibThe metabolism of Trimipramine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Trimipramine can be increased when it is combined with Imidapril.Investigational
ImipramineImipramine may increase the antihypertensive activities of Trimipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Trimipramine.Withdrawn
IndinavirThe metabolism of Trimipramine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Trimipramine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Trimipramine.Approved, Investigational
Iofetamine I-123Trimipramine may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the serotonergic activities of Trimipramine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Trimipramine.Withdrawn
IrbesartanThe metabolism of Trimipramine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Trimipramine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Trimipramine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Trimipramine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trimipramine.Approved, Vet Approved
IsoflurophateThe serum concentration of Trimipramine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsomethepteneTrimipramine may increase the vasopressor activities of Isometheptene.Approved
IsoniazidThe metabolism of Trimipramine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isoprenaline.Approved, Investigational
IsoxsuprineTrimipramine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Trimipramine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Trimipramine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Trimipramine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Trimipramine can be increased when it is combined with Ixazomib.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trimipramine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Trimipramine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Trimipramine.Approved, Nutraceutical, Withdrawn
LabetalolLabetalol may increase the antihypertensive activities of Trimipramine.Approved
LacidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Trimipramine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Trimipramine.Approved
LeflunomideThe metabolism of Trimipramine can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibTrimipramine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LepirudinThe serum concentration of Trimipramine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Trimipramine can be increased when it is combined with Letaxaban.Investigational
LeuprolideTrimipramine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levodopa.Approved
LevofloxacinTrimipramine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levomilnacipran.Approved, Investigational
LevonordefrinTrimipramine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trimipramine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levosalbutamol.Approved, Investigational
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Trimipramine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Trimipramine is combined with Lidoflazine.Experimental
LinagliptinThe serum concentration of Trimipramine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Trimipramine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Trimipramine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Trimipramine.Approved
LisdexamfetamineTrimipramine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Trimipramine can be increased when it is combined with Lisinopril.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Trimipramine.Experimental
LobeglitazoneThe metabolism of Trimipramine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Trimipramine can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Trimipramine is combined with Loperamide.Approved
LopinavirThe metabolism of Trimipramine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Trimipramine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trimipramine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Trimipramine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Trimipramine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Trimipramine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trimipramine.Approved
LuliconazoleThe serum concentration of Trimipramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Trimipramine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineTrimipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trimipramine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Trimipramine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Trimipramine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Maprotiline.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Trimipramine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Medazepam.Experimental
MedetomidineTrimipramine may decrease the antihypertensive activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Trimipramine can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Trimipramine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Trimipramine is combined with Menthol.Approved
MephedroneTrimipramine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineTrimipramine may increase the vasopressor activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Trimipramine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trimipramine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mesoridazine.Approved, Investigational
MetaraminolTrimipramine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trimipramine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trimipramine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineTrimipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trimipramine.Approved, Vet Approved
MethohexitalThe metabolism of Trimipramine can be increased when combined with Methohexital.Approved
MethotrimeprazineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineTrimipramine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineTrimipramine may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methsuximide.Approved
MethyldopaTrimipramine may decrease the antihypertensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methylecgonine.Experimental
Methylene blueTrimipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.Approved, Investigational
MethylphenobarbitalThe metabolism of Trimipramine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimipramine.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Trimipramine.Approved
MibefradilThe risk or severity of hypotension can be increased when Trimipramine is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trimipramine.Approved, Illicit
MidodrineTrimipramine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineTrimipramine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Trimipramine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Trimipramine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Trimipramine is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Trimipramine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved, Investigational
MirabegronThe metabolism of Trimipramine can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Trimipramine.Investigational
MirtazapineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Trimipramine can be decreased when it is combined with Mitotane.Approved
MMDATrimipramine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Trimipramine.Approved, Investigational
ModafinilThe metabolism of Trimipramine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Trimipramine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trimipramine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mosapramine.Experimental
MoxifloxacinTrimipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Trimipramine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Trimipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
NafamostatThe serum concentration of Trimipramine can be increased when it is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of hypotension can be increased when Trimipramine is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trimipramine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trimipramine.Approved
NaphazolineTrimipramine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Naratriptan.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Trimipramine.Approved, Withdrawn
NelfinavirThe metabolism of Trimipramine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Trimipramine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Trimipramine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Trimipramine.Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Trimipramine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Trimipramine.Approved, Investigational
NicorandilTrimipramine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nifedipine.Approved
NiguldipineTrimipramine may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibTrimipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Trimipramine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trimipramine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Trimipramine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Nordazepam.Approved
NorepinephrineTrimipramine may decrease the antihypertensive activities of Norepinephrine.Approved
NorfenefrineTrimipramine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the antihypertensive activities of Trimipramine.Approved
NylidrinTrimipramine may decrease the vasoconstricting activities of Nylidrin.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Trimipramine.Withdrawn
OctopamineTrimipramine may decrease the vasoconstricting activities of Octopamine.Experimental
OfloxacinTrimipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the antihypertensive activities of Trimipramine.Approved, Investigational
OlaparibThe metabolism of Trimipramine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Trimipramine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Trimipramine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronTrimipramine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Trimipramine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Orciprenaline.Approved
OrphenadrineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Trimipramine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Trimipramine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Trimipramine can be increased when it is combined with Otamixaban.Investigational
OtiloniumThe risk or severity of hypotension can be increased when Trimipramine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trimipramine.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trimipramine.Approved, Illicit, Investigational
OxyfedrineTrimipramine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineTrimipramine may decrease the antihypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trimipramine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePaliperidone may increase the antihypertensive activities of Trimipramine.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Trimipramine.Approved, Investigational
PanobinostatThe serum concentration of Trimipramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Trimipramine can be decreased when combined with Pantoprazole.Approved
ParaldehydeTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Trimipramine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trimipramine.Approved
Peginterferon alfa-2bThe serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Penfluridol.Experimental
PentamidineTrimipramine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trimipramine.Approved, Vet Approved
PentobarbitalThe metabolism of Trimipramine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trimipramine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perazine.Approved, Investigational
PerflutrenTrimipramine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideTrimipramine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Trimipramine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trimipramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trimipramine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Trimipramine is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenazocine.Experimental
PhendimetrazineTrimipramine may increase the vasopressor activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Trimipramine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenibut.Experimental
PhenindioneTrimipramine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Trimipramine.Withdrawn
PhenobarbitalThe metabolism of Trimipramine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Trimipramine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Trimipramine.Withdrawn
PhenprocoumonTrimipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineTrimipramine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineTrimipramine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineTrimipramine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Trimipramine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Trimipramine can be increased when it is combined with Phosphoramidon.Experimental
PimozideTrimipramine may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Trimipramine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Trimipramine.Approved
PitolisantThe serum concentration of Trimipramine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Trimipramine.Withdrawn
PizotifenTrimipramine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Trimipramine.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Trimipramine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
PramipexoleTrimipramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Trimipramine.Approved
PregabalinThe therapeutic efficacy of Trimipramine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolTrimipramine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Trimipramine is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prilocaine.Approved
PrimaquineTrimipramine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Trimipramine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Trimipramine can be increased when it is combined with Prinomastat.Investigational
ProcainamideTrimipramine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the serotonergic activities of Trimipramine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Trimipramine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trimipramine.Approved, Vet Approved
PromazinePromazine may increase the antihypertensive activities of Trimipramine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promethazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Trimipramine.Approved
PropanididThe risk or severity of adverse effects can be increased when Trimipramine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Proparacaine.Approved, Vet Approved
PropericiazineTrimipramine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Trimipramine.Approved
PropiverineTrimipramine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trimipramine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Trimipramine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prothipendyl.Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trimipramine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Trimipramine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trimipramine.Approved
PSD502The risk or severity of adverse effects can be increased when Trimipramine is combined with PSD502.Investigational
PseudoephedrineTrimipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Trimipramine can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Trimipramine.Approved, Illicit
QuetiapineQuetiapine may increase the antihypertensive activities of Trimipramine.Approved
QuinaprilThe serum concentration of Trimipramine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineTrimipramine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineTrimipramine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Quinisocaine.Experimental
RacecadotrilThe serum concentration of Trimipramine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineTrimipramine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Raclopride.Investigational
RactopamineTrimipramine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Trimipramine can be increased when it is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trimipramine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Trimipramine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trimipramine.Approved
RemikirenThe serum concentration of Trimipramine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Remoxipride.Approved, Withdrawn
ReproterolTrimipramine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trimipramine.Approved, Investigational
RifabutinThe metabolism of Trimipramine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Trimipramine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Trimipramine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trimipramine.Approved, Investigational
RilmenidineTrimipramine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolTrimipramine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Trimipramine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ritanserin.Investigational
RitobegronTrimipramine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Trimipramine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Trimipramine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Trimipramine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineTrimipramine may decrease the antihypertensive activities of Romifidine.Vet Approved
RopiniroleTrimipramine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ropivacaine.Approved
RotigotineTrimipramine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Trimipramine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trimipramine.Approved
S-3304The serum concentration of Trimipramine can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Trimipramine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Trimipramine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Trimipramine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Trimipramine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe metabolism of Trimipramine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Trimipramine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Trimipramine is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Trimipramine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trimipramine.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Trimipramine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trimipramine.Approved
SiltuximabThe serum concentration of Trimipramine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Trimipramine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Trimipramine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Trimipramine can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
Sodium phosphate, monobasicThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sodium phosphate.Approved
SolabegronTrimipramine may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe metabolism of Trimipramine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolTrimipramine may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilThe serum concentration of Trimipramine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Trimipramine can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Trimipramine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.Approved, Investigational
SulfadiazineThe metabolism of Trimipramine can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Trimipramine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Trimipramine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Trimipramine.Approved, Investigational
SuvorexantTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineTrimipramine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Trimipramine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Trimipramine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Trimipramine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Trimipramine.Approved
TelaprevirThe metabolism of Trimipramine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinTrimipramine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Trimipramine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trimipramine.Approved, Investigational
TemocaprilThe serum concentration of Trimipramine can be increased when it is combined with Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Trimipramine.Approved
TerbinafineThe metabolism of Trimipramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Trimipramine.Approved
TerodilineThe risk or severity of hypotension can be increased when Trimipramine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Trimipramine.Experimental
TetrabenazineTrimipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tetrodotoxin.Investigational
TetryzolineTrimipramine may increase the vasopressor activities of Tetryzoline.Approved
ThalidomideTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Trimipramine.Approved
ThiamylalThe metabolism of Trimipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Trimipramine can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thiopropazate.Experimental
ThioproperazineTrimipramine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Trimipramine.Approved, Withdrawn
ThiorphanThe serum concentration of Trimipramine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trimipramine.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Trimipramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Trimipramine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Trimipramine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
TioclomarolTrimipramine may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Trimipramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTrimipramine may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the antihypertensive activities of Trimipramine.Approved, Vet Approved
TolbutamideThe metabolism of Trimipramine can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trimipramine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Trimipramine is combined with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the serotonergic activities of Trimipramine.Approved
TopiramateThe metabolism of Trimipramine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Trimipramine can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trimipramine.Approved, Investigational
ToremifeneTrimipramine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolTrimipramine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Trimipramine can be increased when it is combined with Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Trimipramine is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the serotonergic activities of Trimipramine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Trimipramine.Approved, Investigational
TretoquinolTrimipramine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Trimipramine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Trimipramine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Trimipramine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Trimipramine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Trimipramine is combined with Trimethadione.Approved
TrimethoprimThe metabolism of Trimipramine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trimipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Trimipramine.Approved, Investigational
TulobuterolTrimipramine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UbenimexThe serum concentration of Trimipramine can be increased when it is combined with Ubenimex.Experimental, Investigational
UdenafilUdenafil may increase the hypotensive activities of Trimipramine.Approved, Investigational
UlinastatinThe serum concentration of Trimipramine can be increased when it is combined with Ulinastatin.Investigational
UrapidilUrapidil may increase the antihypertensive activities of Trimipramine.Investigational
Valproic AcidThe serum concentration of Trimipramine can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Trimipramine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibTrimipramine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Trimipramine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Trimipramine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Trimipramine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Veralipride.Experimental
VerapamilTrimipramine may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Trimipramine.Approved
VildagliptinThe serum concentration of Trimipramine can be increased when it is combined with Vildagliptin.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Trimipramine.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Trimipramine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Trimipramine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Trimipramine.Approved, Investigational
WarfarinTrimipramine may increase the anticoagulant activities of Warfarin.Approved
WIN 55212-2The risk or severity of hypotension can be increased when Trimipramine is combined with WIN 55212-2.Experimental
XamoterolTrimipramine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Trimipramine is combined with Xenon.Experimental
XimelagatranThe serum concentration of Trimipramine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineTrimipramine may decrease the antihypertensive activities of Xylazine.Vet Approved
XylometazolineTrimipramine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Trimipramine.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Trimipramine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Trimipramine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trimipramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Trimipramine.Approved
ZofenoprilThe serum concentration of Trimipramine can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trimipramine.Approved, Investigational
ZolpidemTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Trimipramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Trimipramine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Trimipramine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014864
KEGG Drug
D00394
PubChem Compound
5584
PubChem Substance
46507121
ChemSpider
5382
BindingDB
50240410
ChEBI
9738
ChEMBL
CHEMBL644
Therapeutic Targets Database
DAP001153
PharmGKB
PA451791
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Trimipramine
ATC Codes
N06AA06 — Trimipramine
AHFS Codes
  • 28:16.04.28 — Tricyclics and Other Norepinephrine-reuptake Inhibitors
FDA label
Download (152 KB)
MSDS
Download (75 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4Unknown StatusNot AvailableMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Actavis Group
  • Duramed
  • Professional Co.
Dosage forms
FormRouteStrength
CapsuleOral75 mg
TabletOral100 mg
TabletOral12.5 mg
TabletOral25 mg
TabletOral50 mg
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
Prices
Unit descriptionCostUnit
Trimipramine maleate powder51.0USD g
Surmontil 100 mg capsule5.92USD capsule
Surmontil 50 mg capsule4.15USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Trimipramine 25 mg capsule1.92USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)45 °CPhysProp
water solubilitySlightly solubleNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP4.67ALOGPS
logP4.76ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.02 m3·mol-1ChemAxon
Polarizability35.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9739
Blood Brain Barrier+0.9861
Caco-2 permeable+0.8059
P-glycoprotein substrateSubstrate0.6559
P-glycoprotein inhibitor IInhibitor0.8838
P-glycoprotein inhibitor IIInhibitor0.8826
Renal organic cation transporterInhibitor0.7098
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6698
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9094
CYP450 3A4 inhibitorNon-inhibitor0.6132
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.8109
CarcinogenicityNon-carcinogens0.9021
BiodegradationNot ready biodegradable0.9886
Rat acute toxicity2.8709 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9065
hERG inhibition (predictor II)Inhibitor0.8271
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4m-5790000000-53c724efbeeb45818f39
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-68bace4e48742b76d7b4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-683044c8af33df070967
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-1960000000-2c69c2591b0ff915ccc2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-3920000000-7c68e89e7f53026fdb80
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-4930000000-f1fe2a4f61bfbec6d778
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-7920000000-b085a14dd7e5d88d4922
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-9810000000-b67a0e6866c4bcb27488
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-90da643ba602b4854ad4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-1960000000-953dd8f5d50ce412ae55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-2920000000-493d39be6384cb3b09d4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-4920000000-02c877be6bc360fbe70e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-6920000000-eb3878e47d12e4792744
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-8910000000-5341bd1feea3e6a75bc8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-875e7a40df38e129227c

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / Azepines / Benzenoids / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzazepine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Azepine / Benzenoid / Tertiary aliphatic amine / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, dibenzoazepine (CHEBI:9738)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Diamond M, Kelly JP, Connor TJ: Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4. [PubMed:16388933]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Details
10. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Desensitize the target
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
References
  1. Eikmeier G, Muszynski K, Berger M, Gastpar M: High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial. Pharmacopsychiatry. 1990 Sep;23(5):212-4. [PubMed:1979173]
Kind
Protein
Organism
Rat
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
Htr2c
Uniprot ID
P08909
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51916.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Uhr M, Grauer MT: abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res. 2003 May-Jun;37(3):179-85. [PubMed:12650738]

Drug created on June 13, 2005 07:24 / Updated on July 16, 2018 21:16